Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis
2023 · ESMO Open · 70 citations
https://doi.org/10.1016/j.esmoop.2023.101592
E
Elisa Agostinetto
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
193
Papers
2.6K
Citations
25
h-index
54
i10-index
Elisa Agostinetto is an academic researcher from Université Libre de Bruxelles. The author has contributed to research in topics: Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies & HER2/EGFR in Cancer Research. The author has an h-index of 25, co-authored 165 publications.
ORCID: 0000-0003-0295-7511Papers by this author
worksNeoadjuvant chemotherapy in hormone receptor-positive/HER2-negative early breast cancer: When, why and what?
2021 · Critical Reviews in Oncology/Hematology · 52 citations
https://doi.org/10.1016/j.critrevonc.2021.103280
Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis
2024 · ESMO Open · 48 citations
https://doi.org/10.1016/j.esmoop.2024.102390
Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis
2021 · ESMO Open · 44 citations
https://doi.org/10.1016/j.esmoop.2021.100066
The Future of Breast Cancer Research in the Survivorship Field
2023 · Oncology and Therapy · 34 citations
https://doi.org/10.1007/s40487-023-00225-8
Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar
2024 · Cell Reports Medicine · 32 citations
https://doi.org/10.1016/j.xcrm.2024.101575
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat